Table 4 Comparison of expression levels of SOCS genes in tumoral tissue of breast cancer patients between clinicopathological-based categories (Mean and SD values of (E^CTHPRT/E^CTtarget gene) are presented)
From: Suppressor of cytokine signaling (SOCS) genes are downregulated in breast cancer
SOCS1 expression (mean (SD)) | P value | SOCS2 expression (mean (SD)) | P value | SOCS3 expression (mean (SD)) | P value | SOCS5 expression (mean (SD)) | P value | |
|---|---|---|---|---|---|---|---|---|
Age | ||||||||
< 55 years vs. ≥ 55 years | 496.1 (2.6) vs. 592.9 (2.6) | 0.88 | 1.5 (7.9) vs. 10.9 (17.2) | 0.43 | 199.5 (542.6) vs. 84.7 (372.8) | 0.4 | 16.7 (44.9) vs. 1.1 (4.9) | 0.33 |
ER status | ||||||||
ER (+) vs. ER (−) | 675.4 (2.9) vs. 0.6 (0.8) | 0.55 | 1.2 (7.1) vs. 5.1 (7.7) | 0.64 | 192.5 (545.1) vs. 55.1 (127.2) | 0.51 | 537.3 (3.3) vs. 1.5 (1.5) | 0.68 |
PR status | ||||||||
PR (+) vs. PR (−) | 766.1 (3.1) vs. 2.5 (6.9) | 0.42 | 1.4 (7.5) vs. 4 (5.9) | 0.53 | 216.6 (577.2) vs. 41.5 (102.1) | 0.08 | 609.9 (3.6) vs. 1.2 (1.3) | 0.58 |
HER2 status | ||||||||
HER2 (+) vs. HER2 (−) | 20 (25.1) vs. 781.5 (3.1) | 0.41 | 10.3 (17.8) vs. 1.4 (7.6) | 0.51 | 223.3 (763) vs. 160.9 (411.2) | 0.71 | 3.4 (5.6) vs. 626 (3.6) | 0.56 |
Tumor grade | ||||||||
Grade 1 vs. 2 | 3.4 (6.2) vs. 13.7 (23.4) | 0.004 | 6.5 (1.6) vs. 13.8 (20.6) | 0.04 | 596 (735) vs. 25.7 (63.9) | 0.01 | 2.8 (7.7) vs. 3.8 (7.1) | 0.08 |
Grade 1 vs. 3 | 3.4 (6.2) vs. 8.1 (19.2) | 0.007 | 6.5 (1.6) vs. 10.8 (17.6) | 0.05 | 596 (735) vs. 194.5 (659.3) | 0.1 | 2.8 (7.7) vs. 2.3 (3.9) | 0.1 |
Grade 2 vs. 3 | 13.7 (23.4) vs. 8.1 (19.2) | 1 | 13.8 (20.6) vs. 10.8 (17.6) | 1 | 25.7 (63.9) vs. 194.5 (659.3) | 0.5 | 3.8 (7.1) vs. 2.3 (3.9) | 1 |